At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD
In Brief
A Phase 2 clinical trial evaluating BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, and 1 other intervention for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 360 participants across 37 sites in 3 countries.
Detailed Summary
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 micrograms tiotropium bromide solution for inhalation, delivered by the Respimat inhaler, once daily for four weeks in patients with chronic obstructive pulmonary disease (COPD).
Study Details
Timeline
Interventions
BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation